These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. The novel bis-benzylisoquinoline PY35 reverses P-glycoprotein-mediated multidrug resistance. Cao Z; Wright M; Cheng J; Huang X; Liu L; Wu L; Yang P Oncol Rep; 2014 Sep; 32(3):1211-7. PubMed ID: 25017650 [TBL] [Abstract][Full Text] [Related]
24. D-α-tocopherol polyethylene glycol succinate-based redox-sensitive paclitaxel prodrug for overcoming multidrug resistance in cancer cells. Bao Y; Guo Y; Zhuang X; Li D; Cheng B; Tan S; Zhang Z Mol Pharm; 2014 Sep; 11(9):3196-209. PubMed ID: 25102234 [TBL] [Abstract][Full Text] [Related]
25. Honokiol enhances paclitaxel efficacy in multi-drug resistant human cancer model through the induction of apoptosis. Wang X; Beitler JJ; Wang H; Lee MJ; Huang W; Koenig L; Nannapaneni S; Amin AR; Bonner M; Shin HJ; Chen ZG; Arbiser JL; Shin DM PLoS One; 2014; 9(2):e86369. PubMed ID: 24586249 [TBL] [Abstract][Full Text] [Related]
26. Syl611, a novel semisynthetic taxane derivative, reverses multidrug resistance by p-glycoprotein inhibition and facilitating inward transmembrane action. Zhang Y; Li H; Wang H; Su F; Qu R; Yin D; Dai J; Li Y; Chen X Cancer Chemother Pharmacol; 2010 Oct; 66(5):851-9. PubMed ID: 20052473 [TBL] [Abstract][Full Text] [Related]
27. Bufotalin from Venenum Bufonis inhibits growth of multidrug resistant HepG2 cells through G2/M cell cycle arrest and apoptosis. Zhang DM; Liu JS; Tang MK; Yiu A; Cao HH; Jiang L; Chan JY; Tian HY; Fung KP; Ye WC Eur J Pharmacol; 2012 Oct; 692(1-3):19-28. PubMed ID: 22841670 [TBL] [Abstract][Full Text] [Related]
28. Cetuximab enhanced the efficacy of chemotherapeutic agent in ABCB1/P-glycoprotein-overexpressing cancer cells. Wang F; Chen Y; Huang L; Liu T; Huang Y; Zhao J; Wang X; Yang K; Ma S; Huang L; To KK; Gu Y; Fu L Oncotarget; 2015 Dec; 6(38):40850-65. PubMed ID: 26506420 [TBL] [Abstract][Full Text] [Related]
29. The positive inotropic agent DPI-201106 selectively reverses ABCB1-mediated multidrug resistance in cancer cell lines. Hsiao SH; Murakami M; Yeh N; Li YQ; Hung TH; Wu YS; Ambudkar SV; Wu CP Cancer Lett; 2018 Oct; 434():81-90. PubMed ID: 30031116 [TBL] [Abstract][Full Text] [Related]
30. Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity. Menendez JA; Vellon L; Colomer R; Lupu R Int J Cancer; 2005 May; 115(1):19-35. PubMed ID: 15657900 [TBL] [Abstract][Full Text] [Related]
31. Synergistic effect of folate-mediated targeting and verapamil-mediated P-gp inhibition with paclitaxel -polymer micelles to overcome multi-drug resistance. Wang F; Zhang D; Zhang Q; Chen Y; Zheng D; Hao L; Duan C; Jia L; Liu G; Liu Y Biomaterials; 2011 Dec; 32(35):9444-56. PubMed ID: 21903258 [TBL] [Abstract][Full Text] [Related]
32. PSC 833 induces apoptosis in drug-sensitive human leukemia cell line and modulates resistance to paclitaxel in its multidrug-resistant variant. Duraj J; Takacsova X; Sedlak J; Sulikova M; Hunakova L; Bies J; Chorvath B Anticancer Res; 2000; 20(6B):4627-32. PubMed ID: 11205313 [TBL] [Abstract][Full Text] [Related]
33. Overexpression of human ABCB1 in cancer cells leads to reduced activity of GSK461364, a specific inhibitor of polo-like kinase 1. Wu CP; Hsiao SH; Luo SY; Tuo WC; Su CY; Li YQ; Huang YH; Hsieh CH Mol Pharm; 2014 Oct; 11(10):3727-36. PubMed ID: 25192198 [TBL] [Abstract][Full Text] [Related]
34. Inhibition of protein glycosylation reverses the MDR phenotype of cancer cell lines. Wojtowicz K; Januchowski R; Nowicki M; Zabel M Biomed Pharmacother; 2015 Aug; 74():49-56. PubMed ID: 26349962 [TBL] [Abstract][Full Text] [Related]
35. Induction of actin disruption and downregulation of P-glycoprotein expression by solamargine in multidrug-resistant K562/A02 cells. Li X; Zhao Y; Ji M; Liu SS; Cui M; Lou HX Chin Med J (Engl); 2011 Jul; 124(13):2038-44. PubMed ID: 22088467 [TBL] [Abstract][Full Text] [Related]
36. Paclitaxel-loaded N-octyl-O-sulfate chitosan micelles for superior cancer therapeutic efficacy and overcoming drug resistance. Jin X; Mo R; Ding Y; Zheng W; Zhang C Mol Pharm; 2014 Jan; 11(1):145-57. PubMed ID: 24261922 [TBL] [Abstract][Full Text] [Related]
37. Multidrug resistance reversal agent, NSC77037, identified with a cell-based screening assay. Susa M; Choy E; Yang C; Schwab J; Mankin H; Hornicek F; Duan Z J Biomol Screen; 2010 Mar; 15(3):287-96. PubMed ID: 20150589 [TBL] [Abstract][Full Text] [Related]
38. Reversal of P-glycoprotein-mediated multidrug resistance by guggulsterone in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells. Xu HB; Li L; Liu GQ Pharmazie; 2009 Oct; 64(10):660-5. PubMed ID: 19947169 [TBL] [Abstract][Full Text] [Related]
39. Knockdown of c-MET induced apoptosis in ABCB1-overexpressed multidrug-resistance cancer cell lines. Hung TH; Li YH; Tseng CP; Lan YW; Hsu SC; Chen YH; Huang TT; Lai HC; Chen CM; Choo KB; Chong KY Cancer Gene Ther; 2015 May; 22(5):262-70. PubMed ID: 25908454 [TBL] [Abstract][Full Text] [Related]
40. Cediranib (recentin, AZD2171) reverses ABCB1- and ABCC1-mediated multidrug resistance by inhibition of their transport function. Tao LY; Liang YJ; Wang F; Chen LM; Yan YY; Dai CL; Fu LW Cancer Chemother Pharmacol; 2009 Oct; 64(5):961-9. PubMed ID: 19255759 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]